Skip to main content
Erschienen in: Reactions Weekly 1/2022

01.10.2022 | Case report

Antineoplastics

Lack off efficacy, febrile neutropenia and lung aspergillosis: case report

Erschienen in: Reactions Weekly | Ausgabe 1/2022

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Gonzales F, et al. Ex vivo drug sensitivity profiling-guided treatment of a relapsed pediatric mixed-phenotype acute leukemia with venetoclax and azacitidine. Pediatric Blood and Cancer 69: No. 10, Oct 2022. Available from: URL: http://doi.org/10.1002/pbc.29678 Gonzales F, et al. Ex vivo drug sensitivity profiling-guided treatment of a relapsed pediatric mixed-phenotype acute leukemia with venetoclax and azacitidine. Pediatric Blood and Cancer 69: No. 10, Oct 2022. Available from: URL: http://​doi.​org/​10.​1002/​pbc.​29678
Metadaten
Titel
Antineoplastics
Lack off efficacy, febrile neutropenia and lung aspergillosis: case report
Publikationsdatum
01.10.2022
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2022
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-022-25318-0

Weitere Artikel der Ausgabe 1/2022

Reactions Weekly 1/2022 Zur Ausgabe

Case report

AZD-1222

Case report

Iron

Case report

Regorafenib